Table 3.
Number (percentage%) of patients presenting with none, mild, moderate or severe pain during the treatment
| Severity | None | Mild | Moderate | Severe | ||||
|---|---|---|---|---|---|---|---|---|
| Group | LLLT | DSG/EE | LLLT | DSG/EE | LLLT | DSG/EE | LLLT | DSG/EE |
| PP analysis | ||||||||
| Baseline | 0 | 0 | 21 (29.2) | 21 (33.3) | 25 (34.7) | 20 (31.8) | 26 (36.1) | 22 (34.9) |
| 4th week | 0 | 7 (11.1) | 33 (45.8) | 37 (58.7) | 26 (36.1) | 16 (25.4) | 13 (18.1) | 3 (4.8) |
| 8th week | 6 (8.3) | 10 (15.9) | 34 (47.3) | 43 (68.3) | 26 (36.1) | 9 (14.3) | 6 (8.3) | 1 (1.6) |
| 12th week | 6 (8.3) | 13 (20.6) | 41 (57) | 46 (73.0) | 25 (34.7) | 4 (6.4) | 0 | 0 |
| ITT analysis | ||||||||
| Baseline | 0 | 0 | 21 (26.9) | 25 (32.1) | 30 (38.5) | 28 (35.8) | 27 (34.6) | 25 (32.1) |
| 4th week | 0 | 7 (9.0) | 36 (46.2) | 47 (60.3) | 29 (37.2) | 20 (25.6) | 13 (16.6) | 4 (5.1) |
| 8th week | 6 (7.7) | 10 (12.8) | 38 (48.7) | 55 (70.5) | 28 (35.9) | 12 (15.4) | 6 (7.7) | 1 (1.3) |
| 12th week | 6 (7.7) | 13 (16.6) | 41 (52.6) | 58 (74.4) | 30 (38.4) | 7 (9.0) | 1 (1.3) | 0 |
LLLT, low-level light therapy; DSG/EE, desogestrel and ethinyl estradiol; PP, per protocol; ITT, intention to treat